Novo Nordisk A/S
The global leader in GLP-1 diabetes and obesity treatments — $41 billion in revenue, household-name franchises Ozempic and Wegovy, 44% operating margins, and a 100-year legacy in metabolic disease innovation.
Business Overview
What does Novo Nordisk do, and why is it the global GLP-1 leader?
Novo Nordisk is not just another pharmaceutical company — it is the undisputed global leader in diabetes and obesity care, and the company behind two of the most talked-about drugs in the world: Ozempic and Wegovy. Headquartered in Bagsværd, Denmark, with roots dating back to 1923, Novo Nordisk has spent a century building the deepest expertise in metabolic disease of any company on Earth.
The company's GLP-1 receptor agonist franchise — built around the molecule semaglutide — has transformed both the diabetes and obesity treatment landscapes. Ozempic (injectable semaglutide for type 2 diabetes) generated over $17 billion in 2024, while Wegovy (injectable semaglutide for obesity) more than doubled to $8 billion. Together, these two products alone account for roughly 63% of total company revenue.
Beyond its blockbuster GLP-1 franchise, Novo Nordisk maintains a comprehensive insulin portfolio generating $7.8 billion annually, a growing rare disease segment, and the world's most advanced pipeline of next-generation incretin therapies including cagriSema (triple agonist) and amycretin. The company has also launched an oral formulation of Wegovy in early 2026, dramatically expanding the addressable market by reaching patients who prefer pills over injections.
Novo Nordisk's vertically integrated manufacturing is a critical strategic asset. The 2024 Catalent acquisition added three fill-finish manufacturing sites, complementing a $6 billion Kalundborg facility expansion in Denmark, a $4.1 billion Clayton, North Carolina facility, and a $2.2 billion Chartres, France upgrade. This massive capital investment creates a manufacturing moat that competitors will take years to replicate.
Diabetes Care
71% of revenue (DKK 206.6B). Led by Ozempic ($17B), Rybelsus (oral GLP-1), and a comprehensive insulin portfolio ($7.8B). GLP-1 diabetes products grew 22% at constant exchange rates in 2024.
Obesity Care
22% of revenue (DKK 65.1B). Wegovy generated $8B in 2024, more than doubling YoY. Saxenda contributes additional volume. Obesity segment grew 57% at constant exchange rates — the fastest-growing division.
Rare Disease
7% of revenue (DKK 18.6B). Rare endocrine disorders grew 31% at constant exchange rates. Includes haemophilia, growth disorders, and hormone replacement therapies. Steady, high-margin niche.
Financial Fundamentals
Three tests every quality business must pass
Moat Analysis
Five dimensions that determine competitive durability
Brand Loyalty & Pricing Power
9/10Ozempic and Wegovy are household names — arguably the most recognised pharmaceutical brands in the world right now. Physicians prescribe semaglutide by brand name, patients request it specifically, and the clinical evidence base (including cardiovascular risk reduction data) creates deep prescriber confidence. Novo commands premium pricing with exceptional brand equity built over a century of diabetes innovation.
High Barriers to Entry
9/10Semaglutide is a complex GLP-1 peptide biologic, fundamentally different from simple small-molecule drugs. Manufacturing requires sophisticated API production with sterile fill-finish capabilities that take years to build. Novo holds 320+ patent applications (154 granted) with US protection through 2032 and additional formulation patents extending to 2042. The $11B Catalent acquisition and $12B+ in manufacturing capex create physical barriers no competitor can quickly replicate.
High Switching Costs
8/10Once a patient stabilises on semaglutide with good results, neither the patient nor their physician wants to risk switching to an unproven alternative. Treatment protocols, dose titration schedules, insurance formulary positions, and prior authorisation approvals all create inertia. Payer contracts and preferred formulary status add institutional switching costs. The clinical evidence base for semaglutide (including SELECT cardiovascular trial) gives prescribers confidence that competitors' products must match.
Network Effect
6/10Moderate network effects through Novo's century-long proprietary patient/physician data ecosystem. More patients on semaglutide generates more real-world clinical data, which improves prescriber confidence, attracts more patients, and accelerates regulatory approvals for new indications. Novo is building AI models on proprietary data to generate novel insights. However, this is not a true platform network effect like a marketplace or social network.
Economies of Scale
9/10$41 billion in annual revenue makes Novo Nordisk the largest GLP-1 manufacturer in the world by a significant margin. This scale enables 44% operating margins, massive R&D reinvestment, $12B+ in manufacturing capex, and the world's most efficient semaglutide API production. The Catalent acquisition and Kalundborg mega-facility provide vertically integrated manufacturing that competitors simply cannot match for years. Fixed cost absorption across the largest GLP-1 user base creates a durable cost advantage.
Bull & Bear Thesis
Both sides of the coin — so you can decide for yourself
Bull Case
Bear Case
Growth Drivers
Where the next wave of revenue comes from
Oral Wegovy Adoption
The January 2026 launch of oral Wegovy is already reaching 246,000 patients across 70,000+ US pharmacies. The oral formulation's lower price point and convenience (pill vs injection) dramatically expands the addressable market. International rollout throughout 2026 adds further volume. This could be the single largest growth catalyst for Novo Nordisk in the near term.
Next-Gen Pipeline
CagriSema (triple GLP-1/GIP/glucagon agonist) and amycretin represent Novo's post-semaglutide future with potentially superior efficacy. Multiple oral incretin candidates are advancing through clinical trials. The Akero Therapeutics acquisition adds hepatic disease programmes. These pipeline assets are critical to bridging the 2032 patent cliff.
Global Obesity Market Expansion
GLP-1 penetration remains remarkably low — only ~7% of eligible US patients are on treatment. The global obesity epidemic affects 1 billion+ people, making this potentially a $150B+ market by 2030. As awareness grows, insurance coverage expands, and prices become more accessible through oral formulations, the addressable market continues to grow exponentially.
Manufacturing Capacity Ramp
Novo's massive manufacturing investments are coming online: Catalent fill-finish sites reaching full capacity, the new Clayton, NC facility ramping production, and the Kalundborg mega-expansion alleviating supply constraints. This enables margin expansion, broader patient access, and the ability to meet surging demand for both injectable and oral GLP-1 formulations.
Investment Risks
Every investment has risks — here is what could go wrong
Eli Lilly Competitive Threat
Eli Lilly's tirzepatide (Zepbound/Mounjaro) has demonstrated superior weight loss in head-to-head clinical data and is gaining market share rapidly. Lilly's patents extend into the late 2030s, giving it a longer runway of exclusivity. If Lilly continues to outperform on efficacy and gains preferred formulary status with major insurers, Novo could face sustained market share erosion in its core GLP-1 franchise.
High SeverityUS Pricing Pressure & Government Negotiation
The US government's negotiated Maximum Fair Price of $274/30-day supply is a 71% discount that directly impacts revenue. Novo has guided for a 5-13% sales decline in 2026. This pricing precedent could extend to other products and markets, structurally compressing margins. The political environment around drug pricing continues to intensify, and further price negotiations are likely in coming years.
High Severity2032 Semaglutide Patent Cliff
Core US semaglutide patents expire in 2032, exposing $25B+ in annual revenue to biosimilar/generic competition. Sandoz and Apotex have already launched semaglutide generics in Canada as of January 2026. Historical data shows 80-90% price erosion within five years of generic entry. Novo's pipeline must deliver commercially successful successors before 2032 or face a significant revenue cliff.
High SeverityGeographic Patent Expiry in 2026
Semaglutide patents are expiring in China, India, Brazil, and Canada in 2026, enabling domestic competitors and generic manufacturers to enter these large markets. While the US market (protected through 2032) accounts for the majority of revenue, these international markets represent meaningful growth opportunities that are now at risk. Estimated 5-10% revenue headwind from geographic loss of exclusivity.
Medium SeverityValuation & Intrinsic Value
What is this business actually worth?
As of 19 February 2026, Novo Nordisk A/S (NVO) is trading at approximately 35% below its estimated intrinsic value based on our discounted cash flow model. With 25.6% ROIC, a fortress balance sheet at 0.48x net debt/EBITDA, 44% operating margins, global GLP-1 leadership through Ozempic and Wegovy, and US patent protection through 2032, the current discount appears driven by transitory 2026 pricing headwinds and competitive concerns that overweight near-term challenges while underestimating long-term value.
Download the Mintin5 app for the latest update on valuation details, fair value estimates, and margin of safety calculations for NVO and 100+ other stocks.
Download Mintin5 for Valuation DetailsDisclaimer
This research is for educational purposes only and does not constitute financial advice. The information presented is based on publicly available data and our independent analysis. Always do your own research and consult a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.